Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990114 | 0.91 | GRM5 (0.64) | GRM5MEN1KMT2APROKR1 | |
| SCHEMBL990804 | 0.82 | GRM5 (0.69) | GRM5MEN1KMT2AVNN1 | |
| SCHEMBL990896 | 0.80 | GRM5 (1.00) | GRM5KMT2A | |
| SCHEMBL1427046 | 0.77 | MEN1 (0.59) | GRM5MEN1KMT2A | |
| SCHEMBL423467 | 0.77 | KMT2A (0.59) | GRM5MEN1KMT2A | |
| SCHEMBL990373 | 0.75 | GRM5 (0.81) | GRM5 | |
| SCHEMBL991591 | 0.71 | GRM5 (1.00) | GRM5MEN1KMT2A | |
| SCHEMBL990088 | 0.71 | GRM5 (1.00) | GRM5MEN1KMT2A | |
| SCHEMBL990455 | 0.71 | GRM5 (1.00) | GRM5MEN1KMT2A | |
| SCHEMBL423103 | 0.69 | GRM5 (0.48) | GRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1966144-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007071358-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GRM5 1/4885MEN1 4664/4885KMT2A 1101/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885MEN1 4674/4885KMT2A 1058/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | GRM5 680/4885MEN1 2366/4885KMT2A 2663/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885MEN1 4674/4885KMT2A 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.